Request an Appointment:
Online or Call 1-888-824-0200


University of Chicago Medicine cancer experts talk about the latest in mesothelioma care and research, including new treatments, the genetics of the disease, advanced surgical techniques and patient-focused supportive care services.

For more than 25 years, the University of Chicago Medicine Comprehensive Cancer Center has been a pioneer in the treatment and research of malignant mesothelioma -- a rare disease that affects approximately 3,000 Americans each year. Our multidisciplinary team of mesothelioma experts offers the full range of tailored treatment options, from surgery and chemotherapy, to radiation therapy and clinical trials of promising new treatments. A key feature of our program is the availability of HIPEC (hyperthermic intraperitoneal chemoperfusion), a targeted treatment that delivers heated chemotherapy directly into the abdomen to kill residual cancer cells after tumor removal surgery. Thanks to this focused expertise, our mesothelioma program is one of the largest in the United States and cares for patients from throughout the greater Midwest.

HIPEC for mesothelioma

Our program is comprised of a dedicated team of medical oncologists, thoracic surgeons, general surgeons, nurses, pathologists, imaging specialists, and scientists who understand the unique characteristics of this disease. A unique feature of our program is a dedicated nurse navigator who focuses on coordinating care for mesothelioma patients. We use a team approach with weekly mesothelioma program meetings. Our comprehensive and multidisciplinary focus is a direct reflection of our clinical interest in mesothelioma and our expertise in developing novel treatment protocols that extend lives.

Participate in a clinical trial

The testing and use of promising new approaches for mesothelioma--such as chemotherapy, immunotherapies and novel targeted agents, and surgery -- is one of our highest priorities. Many of our clinical trials are performed in collaboration with the National Cancer Institute, drug manufacturers, and other institutions. The University of Chicago plays a key role in the conception and evaluation of these treatments, and is positioned to offer the most diverse treatment options to patients. We have many different options available, so we can tailor the right treatment for each patient.

Our primary goal at the University of Chicago Medicine is to identify and develop treatment regimens to improve the quality of our patients' lives and to eradicate mesothelioma as a life-threatening disease. The opportunities in our clinical research program to deliver focused, targeted therapies give us confidence that survival of mesothelioma patients will continue to improve as they have in the past.

More Information